Similar articles

• Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Feb 8;63(1617):e25-e27. Med Lett Drugs Ther. 2021. PMID: 33757114 Review. No abstract available.
• Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.

  Kang C. Kang C. Target Oncol. 2024 Mar;19(2):289-296. doi: 10.1007/s11523-024-01036-1. Epub 2024 Mar 6. Target Oncol. 2024. PMID: 38446351 Review.
• Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.

  Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A. Spring LM, et al. Oncologist. 2021 Oct;26(10):827-834. doi: 10.1002/onco.13878. Epub 2021 Jul 10. Oncologist. 2021. PMID: 34176192 Free PMC article. Review.
• Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.

  Seligson JM, Patron AM, Berger MJ, Harvey RD, Seligson ND. Seligson JM, et al. Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17. Ann Pharmacother. 2021. PMID: 33070624 Review.
• FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.

  Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, Tang S, Hamed SS, Song P, Charlab R, Dorff SE, Ricks TK, Barnett-Ringgold K, Dinin J, Goldberg KB, Theoret MR, Pazdur R, Amiri-Kordestani L, Beaver JA. Wahby S, et al. Clin Cancer Res. 2021 Apr 1;27(7):1850-1854. doi: 10.1158/1078-0432.CCR-20-3119. Epub 2020 Nov 9. Clin Cancer Res. 2021. PMID: 33168656 Clinical Trial.